

## Special Issue

# Novel Biomarkers in Alzheimer's Disease

### Message from the Guest Editor

Alzheimer's disease (AD) is the most common form of dementia in the elderly, affecting about 46 million people worldwide. It is clinically characterized by the progressive deterioration of memory and other cognitive functions that results in the loss of autonomy and which ultimately requires full-time medical care. The diagnosis of AD currently relies on clinical criteria, including mental status assessment, neurological examination, and brain imaging tests. However, these imaging methods are conclusive only in the advanced stages of disease, whereas AD physiopathology begins several decades before onset of the first symptoms. It is therefore particularly important to identify potential biomarkers that can be used in the early detection of AD, i.e., before clinical signs appear, as well as to evaluate the efficiency of therapeutic agents under testing and to thus accelerate the therapeutic discovery process. In this Special Issue, the current knowledge as well as future perspectives on the role of biomarkers in screening, diagnosis, treatment and follow-up of Alzheimer's disease will be discussed.

### Guest Editor

Dr. Chiara Villa

Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy

### Deadline for manuscript submissions

closed (5 July 2020)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/33684](https://mdpi.com/si/33684)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).